[Special Stock] Aju IB, $1.5 Trillion Technology Export to US Biotech Investor... Huge Success with Precision Investment
[Asia Economy Reporter Park Hyungsoo] Amid a sharp decline in the domestic stock market, the stock price of Aju IB Investment is showing strength. News of excellent performance in its bio portfolio investments appears to be influencing the stock price.
As of 9:18 AM on the 26th, Aju IB Investment is trading at 4,235 KRW, up 3.42% from the previous day.
On the previous day, an economic newspaper reported that the US company Molecular Templates recently signed a large-scale license out contract with the global pharmaceutical company Bristol Myers Squibb. Molecular Templates is a US-based cancer treatment development company. They signed a license out contract worth $1.37 billion (approximately 1.5 trillion KRW) with Bristol Myers Squibb.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- [Seoul, Now] Redevelopment Speed Pledge No.1: Without On-Site Insight, It Becomes the First Failure
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Aju IB Investment entered the US market in December 2013. As of the end of last year, it had invested in a total of 29 companies, 15 of which are listed on NASDAQ. In 2014, Aju IB Investment invested in Molecular Templates through its US local subsidiary, SolarStar Ventures. It is known to have participated as an early investor and achieved a high investment return.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
